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Summary
Objective: To assess the usefulness of sputum examination at 2-months into Continuation Phase (CP) to declare treatment
outcome.
Methodology: It is a retrospective study conducted in one tuberculosis unit, Tiruvallur district of Tamilnadu among smear
positive patients treated with Category I and Category II regimens from May, 1999 – December, 2003.
Results: Sputum was collected at 2-months into CP from 70% of 1551 Category I and 74% of 292 Category II patients declared
cure, failed or treatment completed. Result at 2-months CP was used for giving outcome in 112 (10.3%) of 1088 Category I
patients and 37 (17%) of 217 Category II patients.
Conclusion: In practice, sputum needs to be collected for 7.8% of the patients with smear positive at the end of Intensive Phase.
By doing so, there will be a delay of 1 month for 3.6% of the patients in declaring ‘failure’. By deferring the sputum examination
at 2 months into CP, workload of laboratory technicians can be reduced by about 30%.
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BACKGROUND
Sputum microscopy for acid-fast bacilli
(AFB) is an accepted tool to diagnose and monitor
the progress of pulmonary tuberculosis cases
globally1. For monitoring progress, sputa are
examined at the end of intensive phase (IP), 2-months
into the continuation phase (CP) and end of
treatment2.  Sputum smear result at 2-months of
intensive phase is to decide the need for extension
of IP or going on to CP. Smear at 2-months into CP,
helps to identify failure cases and is also useful to
declare a patient ‘cured’ in case smear at end of IP
is positive. End of the treatment smear is necessary
to give treatment outcome. ‘Cure’ is defined as
‘initially smear positive patient having negative smear
during follow up on two occasions out of which
one is at the end of treatment’. The present paper
reports on the utility of sputum examination at 2-
months into CP to decide the treatment outcome
among sputum positive patients treated with Category
I (CAT I) and Category II (CAT II) regimens.
We undertook a retrospective analysis of
patients treated with CAT I (2EHRZ3/4RH3) and CAT
II (2SHREZ3/1HREZ3/5RHE3)2 regimens of Directly
Observed Treatment Short-course (DOTS) strategy
from May 1999 to December 2003 from one
tuberculosis unit (TU) area of Tiruvallur district,
Tamilnadu.
RESULTS
Among 1893 patients admitted to CAT I
treatment, 1447 (76 %) were declared ‘cured’, 257
(14%) ‘defaulted’, 85 (4%) ‘died’, 94 (5%) ‘failed’
and 10 cases ‘treatment completed’. Corresponding
figures for 575 CAT II patients were 237 (41%),
242 (42%), 41 (7%), 52 (9%), and 3, respectively.
Of these 1893 CAT I patients, 1551 were
declared ‘cured’, ‘failure’ or ‘treatment completed’
and were eligible for sputum collection at 2-months
into CP. Sputum was collected from 1088 (70%)
patients (Table).  Of these, 1012 (93.0%) specimens
were negative at   2-months into CP, of which 955
(94.4%) were not useful to declare the outcome as
‘cure’, as these patients were sputum smear negative
at end of IP and end of treatment. For the remaining
57 (5.6%) patients, the sputum was negative at 2-
months into CP and was useful for declaring the
outcome as ‘cure’ as these patients were sputum
positive at the end of IP. Among 76 patients who
were positive at 2-months into CP, 21 were negative
at the end of IP and end of treatment for declaring
as ‘cure’; hence 2-months CP result was of no
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consequence. For the remaining 55 (72.4%) who
were subsequently positive, the 2-months CP result
was useful to declare them as ‘failure’. Overall
sputum result at 2-months into CP was useful for
112 (10%) of 1088. Out of 112 patients, sputum
was negative for 29 patients at the end of IP and
positive at 2-months into CP. These  patients  will be
declared as ‘failure’ if they  continue to be  sputum
positive at 5th month also. If sputum was not
examined at 2 months into CP, these patients would
have been declared as ‘failure’ at 6 months, with a
delay of one month. Smear results at 2-months into
CP was really useful to give outcome only for the
remaining 83 (7.6%) of 1088 patients who were
smear positive at the end of IP.
 Similarly, among 575 CAT II patients
registered, 292 were eligible for collection at 2-
months into CP and sputum was collected from 217
(74.3%) (Table).  One hundred and seventy seven
patients were smear negative at 2-months into CP
but only 3% (5 of 177) of the result was utilized for
declaring the outcome as ‘cure’. Among 40 patients
who were positive at 2-months into CP, 32 (80%)
was useful for declaring the outcome as ‘failure’.
Overall only 17% (37 of 217) of the smear result at
2-months into CP was utilized for outcome. Eighteen
of 37 patients with smear negative at the end of IP
would have been declared ‘failure’ with a delay of 1
month if sputum was not examined at 2-months into
CP. Smear results at 2-months into CP was useful to
give outcome only for the remaining 19 (8.8%) of
217 patients who were smear positive at the end of
IP.
Significantly more patients were absent for
 
CAT I  CAT II Total 
 No. % No. % No. % 
 
Total admitted 1893  575  2468  
 
Eligible for sputum collection at 2m  CP  
(‘cure’, ’failure’ and ‘treatment completed’) 1551  292  1843  
 
 2m CP specimen collected 1088 70.1 217 74.3 1305 70.8 
 
2m CP -  smear negative 1012 93.0 177 81.6 1189 91.1 
 
Used for treatment outcome  ‘cure’-(a) 
( End of IP smear positive)  57  5    62  
 
Not used treatment out come  ‘cure’ 
( End of IP  – smear negative) 955  172  1127  
 
2m CP - smear positive 76 7.0 40 18.4 116 8.9 
 
Used for treatment outcome  ‘failure’- (b) 
(End of IP negative and subsequent positive) 29  18  47  
 
Used for treatment outcome  ‘failure’-(c)  
(End IP and subsequent  positive) 26       14  40  
 
Not used treatment outcome  ‘cure’ 
(End of IP and end of treatment  negative 21  8  29  
 
2m CP - used for treatment outcome- (a+b+c)  112 10.3 37 17.1 149 11.4 
 
Table: Utilization of sputum result of 2-month into CP for treatment outcome among category I and
II patients treated under DOTS
A. THOMAS ET  AL
Indian Journal of Tuberculosis
39
sputum examination at 2-months into CP among
patients near to non-microscopy centre (34%; 112
of 326) compared to microscopy centre (29%; 351
of 1225) (P<0.05); aged 45 years or more (33%;
229 of 691 vs. 27%; 234 of 860: P<0.05) and
alcoholics (35%; 173 of 493 vs. 27%; 267 of 1003:
P<0.001). In total, for CAT I and CAT II combined,
only for 11.4% (149 of 1305) of patients, the result
at 2-months into CP was used for declaring the
outcome. Among the 149 patients, 47 (3.6%) would
have been declared failure with a delay of 1 month
had sputum not been examined at 2-months into CP.
Sputum need to be examined only for the remaining
102 (7.8%) patients with positive smear at the end
of IP.
DISCUSSION
Our finding indicates that sputum results at
2-months into CP has been useful mainly for patients
who were smear positive at the end of IP, to define
the treatment outcome.  Sputum collection at 2-
months into CP is done for patients who are initially
smear positive. Since continuation of treatment in
the CP with the same drugs is not dependent on the
results of 2-months into CP, DOT provider is likely
to miss to collect the specimens. In our study,
sputum was not collected for 30% of patients at 2-
months into CP among eligible CAT I patients.  Non-
collection of sputum was associated with type of
centre, alcoholism and age of the patient. However,
this has not influenced decision of treatment
outcome. A small proportion (3.6%) of patients (CAT
I and CAT II) for whom sputum was negative at the
end of IP but found to be positive at 2-months into
CP, could be the group for whom there is likelihood
of delay of 1 month to declare ‘failure’.   If patients
visit the health facility for the sputum examination in
the 2-months into CP, they may have an added
advantage of being motivated by the medical officer.
But if we insist on the sputum examination at the
stage, the DOT provider may not give the remaining
CP drugs till sputum is given and the results become
available.
Zhao et al3,4 reported that end of IP sputum
results are predictors of outcome and sputum
conversion during the third month of treatment is an
important predictor of treatment success; failure to
convert predicts treatment failure. Wilkinson et al5
reported that with CAT I treatment in the absence of
initial drug resistance, rifampicin-based short course
chemotherapy results in microbiological cure of
almost all patients who complete treatment, thus
making routine follow-up smear examinations a low
priority. Follow-up smear examination may remain
necessary in countries with high rates of drug
resistance or in persons with an unfavourable clinical
course.
Our findings also showed that the smear
results at 2-months into CP was required only
for patients (CAT I; 7.6% and CAT II; 8.8%),
who were smear positive at the end of IP. For
the patients who were likely to be positive at 2-
months into CP, there would be a delay of 1
month to declare them ‘failure’ as sputum is
examined at the end of treatment. Of 3 occasions
during follow up, if we cut down sputum
examination at 2-months into CP, there will be
about 30% reduction in the work load of sputum
examination during follow up.  Based on these
findings, resources and time and energy of
workers and patients can be saved by deferring
routine sputum examination at 2- months into
CP for patients with smear negative at the end
of IP.
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